Intellia Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NTLA research report →
Companywww.intelliatx.com
Intellia Therapeutics, Inc. , a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.
- CEO
- John Leonard
- IPO
- 2016
- Employees
- 403
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $1.38B
- P/E
- -3.68
- P/S
- 20.81
- P/B
- 2.34
- EV/EBITDA
- -3.32
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -31.89%
- Op Margin
- -636.56%
- Net Margin
- -597.04%
- ROE
- -57.27%
- ROIC
- -59.98%
Growth & Income
- Revenue
- $67.67M · 16.92%
- Net Income
- $-412,694,000 · 20.49%
- EPS
- $-3.81 · 27.43%
- Op Income
- $-440,990,000
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $28.25
- 52W Low
- $6.83
- 50D MA
- $13.60
- 200D MA
- $13.22
- Beta
- 1.93
- Avg Volume
- 5.61M
Get TickerSpark's AI analysis on NTLA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 1, 26 | LEONARD JOHN M | other | 156,400 |
| Mar 1, 26 | LEONARD JOHN M | other | 225,400 |
| Mar 1, 26 | BASTA JAMES | other | 46,080 |
| Mar 2, 26 | BASTA JAMES | sell | 1,211 |
| Mar 1, 26 | BASTA JAMES | other | 65,829 |
| Mar 1, 26 | Lebwohl David | other | 9,943 |
| Mar 1, 26 | Lebwohl David | other | 14,204 |
| Mar 1, 26 | Dulac Edward J III | other | 61,280 |
| Mar 1, 26 | Dulac Edward J III | other | 87,543 |
| Mar 1, 26 | Schultes Birgit C | other | 39,200 |
Our NTLA Coverage
We haven't published any research on NTLA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NTLA Report →